Ansell (ANN) H1 2025 earnings summary

Executive summary

• Achieved double-digit top and bottom-line growth in FY25 H1, meeting or exceeding all objectives, with sales up 29.9% to $1,019.7m and organic constant currency growth of 12.5%.

• KBU acquisition completed July 1, 2024, contributed $140.9m in sales and $34.8m EBIT, with integration ahead of plan and synergy realization expected earlier than planned.

• EBIT increased 62.9% to $127.4m, margin improved to 12.5% from 10.0%, and net profit attributable to shareholders rose 183.5% to $55.0m.

• APIP program delivered $22m in pre-tax savings in H1, with cumulative $43m over the last twelve months and on track for $50m pre-tax savings by FY26.

• Increased Adjusted EPS guidance to US118¢–US128¢ for FY25, reflecting confidence in ongoing performance.

Financial highlights

• Revenue: $1,019.7m (up 29.9% year-over-year; organic constant currency up 12.5%).

• Adjusted EPS up 35.5% to 55.7¢; Statutory EPS up 143.9% to 37.8¢.

• EBIT up 62.9% to $127.4m; EBIT margin at 12.5%, best first half result in recent years.

• Operating cash flow of $129.8m with cash conversion at 104%.

• Interim dividend declared: 22.20¢ per share, up 34.5%.

Outlook and guidance

• FY25 Adjusted EPS guidance raised to US118¢–US128¢, with H2 organic growth expected to continue but at a slower pace.

• Pricing actions and reduced air freight to support H2 earnings; KBU cost synergies to begin realization in H2.

• CapEx guidance maintained at $60–70m, focused on India Surgical facility completion and further deleveraging.

• Tariff increases on US imports to be offset by pricing; limited cost impact expected in H2.

• Dividend payout policy maintained at 40–50% of net profit (excluding one-offs).